



14 December 2023
EMA/MB/490304/2023 - Adopted
Management Board

Agenda for the 122nd meeting of the Management Board

Held on 13 December 2023, Room 1C (14:00 – 18:30hrs)

Held on 14 December 2023, Room 1C (09:00 – 16:00hrs)

Chairperson: Lorraine Nolan

Item	Title	MB action
1.	Draft agenda	For adoption, EMA/MB/490304/2023*
2.	Declarations of competing interests related to the current agenda	Oral report
3.	Minutes from the 121 st meeting, held on 5 October 2023 adopted by written procedure	EMA/MB/490331/2023*
4.	Update on 30 Churchill Place (<i>in camera</i>)	Oral report
A	Points for automatic adoption/endorsement	
A.1	Revision of budget remarks for budget 2024	For automatic endorsement, EMA/MB/217963/2023
A.2	Financial compensation and workload estimation of the NCA participation in the linguistic checking of product related information for 2024	For automatic endorsement, EMA/MB/56455/2023
A.3	Amendment to model rules on types of post and post titles	For automatic endorsement, EMA/MB/337202/2023, EMA/MB/293131/2023
B	Points for discussion	
B.1	Highlights of the Executive Director	Oral report
B.2	Report from the European Commission	Oral report
B.3	Update on the implementation of Veterinary Medicinal Products Regulation	Oral report
B.4	a) Audit strategy/plan 2024-2026 & update of annual audit plan 2023 b) Revised Internal Audit Charter of the Audit Capability of the European Medicines Agency	For information EMA/MB/496331/2023; For adoption, EMA/438866/2023; For information EMA/MB/505479/2023; For adoption, EMA/209787/2017
B.5	Update on Cyber Security	Oral report



Item	Title	MB action
B.6	Update from HMA/EMA Transparency Working Group	Oral report
B.7	Report from PRAC chair	Oral report
B.8	Programming 2023 a) Preparation of written procedure on Amending Budget 01-2023 b) Preparation of written procedure for on non-automatic carry over 2023-2024	For information, EMA/MB/556503/2023, EMA/MB/484957/2023
	Programming 2024-2027 c) Final programming document 2024-2026 d) Preliminary programming document 2025-2027	For information, EMA/MB/536297/2023, EMA/MB/506256/2023; For adoption, EMA/426707/2023*, EMA/533652/2023
B.9	Review and update of European Medicines Agencies Network Strategy (EMANS) to 2028	Oral report,
B.10	Agile transformation and Portfolio status report	For information, EMA/MB/552550/2023, EMA/507481/2023
B.11	Report on Pharmacogenomics activities at EMA	Oral report
B.12	Big Data Steering Group progress report a) Update on BDSG activities b) Multi-year Network Artificial Intelligence workplan	Oral report; For endorsement, EMA/539885/2023*
Demo and posters sessions on Artificial Intelligence (AI) and International activities at EMA		
B.13	Report to the Management Board on ACT EU, the operation of CTIS and the Clinical Trial Regulation	For information, EMA/MB/540758/2023, EMA/MB/509165/2023
B.14	Update of HMA/EMA Task Force on Availability (TF-AAM), including Union list of critical medicines	Oral report
B.15	Quality Innovation Group update	Oral report
B.16	Annual report on the implementation of the EMA's Anti-Fraud Strategy	Oral report
B.17	Report on the data protection activities by EMA in accordance with the EU Data Protection Regulation	Oral report
C	Points for information only**	
C.1	Feedback from the Heads of Medicines Agencies	
C.2	Outcome of written procedures finalised during the period from 27 September 2023 to 06 December 2023	For information, EMA/MB/432308/2023*

Item	Title	MB action
C.3	a) summary of transfers in budget 2024 b) summary of implementation of assigned revenue	For information, EMA/MB/557093/2023, EMA/557095/2023

* Documents marked with a star * are intended for publication on the external website.

** Documents in *Additional documents for information* section are not intended for discussion unless specifically requested.